TARS

Tarsus Pharmaceuticals Inc

68.20

Oct 23 • 3:59 PM ET -3.88 (-5.38%)

68.20

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Oct 23, 6:31 PMNo clear catalyst identified; Tarsus slides amid broad biotech and market weakness

Peers: OCUL LENZ BLCO OCS HROW ARQT ALC ALDX EYPT GKOS

| Held by: VTI FBT IWM VXF IWO IBB VTWO PJP SCHA IHE

Index	RUT
Market Cap	3.36B
Enterprise Value	3.00B
Income	-46.48M
Sales	606.33M
Book/sh	8.01
Cash/sh	9.12
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	370
IPO	Oct 16, 2020

P/E	-
Forward P/E	66.60
PEG	-
P/S	5.55
P/B	8.51
P/C	7.48
P/FCF	60.04
EV/EBITDA	-
EV/Sales	4.95
Quick Ratio	3.17
Current Ratio	3.20
Debt/Eq	0.26
LT Debt/Eq	0.26
Option/Short	Yes / Yes

EPS (ttm)	-1.08
EPS next Y	1.02
EPS next Q	-1.49
EPS this Y	-32.52%
EPS next Y	148.60%
EPS next 5Y	-
EPS past 3/5Y	14.26% -3.80%
Sales past 3/5Y	159.54% -
EPS Y/Y TTM	53.58%
Sales Y/Y TTM	105.17%
EPS Q/Q	10.97%
Sales Q/Q	69.41%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-124.19% 2.51%

Insider Own	5.38%
Insider Trans	-3.37%
Inst Own	95.22%
Inst Trans	2.77%
ROA	-8.40%
ROE	-13.68%
ROIC	-10.67%
Gross Margin	93.28%
Oper. Margin	-8.00%
Profit Margin	-7.67%
SMA20	-6.32%
SMA50	-9.11%
SMA200	0.47%
Trades

Shs Outstand	49.30M
Shs Float	46.65M
Short Float	13.01%
Short Ratio	7.23
Short Interest	6.07M
52W High	91.53 -25.49%
52W Low	53.89 26.55%
Volatility	5.14% 4.37%
ATR (14)	3.30
RSI (14)	39.83
Beta	0.34
Rel Volume	0.66
Avg Volume	839.47K
Volume	556,644

Perf Week	0.19%
Perf Month	-10.22%
Perf Quarter	13.44%
Perf Half Y	10.98%
Perf YTD	-16.71%
Perf Year	-0.18%
Perf 3Y	422.61%
Perf 5Y	148.36%
Perf 10Y	-
Recom	1.09
Target Price	100.00
Prev Close	72.08
Price	68.20
Change %	-5.38%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-26	Resumed	Goldman	Buy	$116
Sep-16-26	Resumed	Barclays	Overweight	$110
Apr-24-26	Resumed	Oppenheimer	Outperform	$105 → $98
Dec-09-25	Initiated	Barclays	Overweight	$100
Nov-20-25	Initiated	Mizuho	Outperform	$100
Jun-02-25	Resumed	Oppenheimer	Outperform	$75
May-27-25	Resumed	H.C. Wainwright	Buy	$72
Nov-20-23	Initiated	Goldman	Neutral	$19
Jul-18-23	Initiated	William Blair	Outperform	$44
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight	$40
Dec-21-21	Initiated	H.C. Wainwright	Buy	$40
Nov-23-21	Initiated	Oppenheimer	Outperform	$55
Nov-10-20	Initiated	Raymond James	Strong Buy	$39
Nov-10-20	Initiated	Ladenburg Thalmann	Buy	$42
Nov-10-20	Initiated	Jefferies	Buy	$35
Nov-10-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Oct-15-26 08:41AM	Lisata adds biopharma finance veteran Jeffrey Farrow to board (Proactive)
Sep-29-26 08:30AM	Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting (GlobeNewswire)
Sep-04-26 08:38AM	Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care (GlobeNewswire) +9.10%
Sep-01-26 04:30PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.76%
Aug-07-26 08:13AM	Tarsus joins Stargardt race to market with $800m Alkeus takeover (Pharmaceutical Technology)
03:02PM	Loading…
Aug-06-26 03:02PM	Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ... (GuruFocus.com) +6.59%
10:07AM	Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M (BioPharma Dive)
07:03AM	Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth (GlobeNewswire)
07:02AM	Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing (GlobeNewswire)
07:01AM	Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position (GlobeNewswire)
Aug-05-26 08:02PM	Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 (GlobeNewswire)
Jul-13-26 04:05PM	Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth (GlobeNewswire) -5.40%
Jul-10-26 04:04AM	ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership (BioPharma Dive) -9.35%
Jul-08-26 04:05PM	Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101 (GlobeNewswire) -5.30%
Jul-01-26 03:28PM	TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme (Stocktwits)
04:30PM	Loading…
May-28-26 04:30PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-26 08:30AM	Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans (GlobeNewswire)
May-07-26 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-29-26 04:30PM	Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 (GlobeNewswire)
Mar-31-26 08:30AM	Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease (GlobeNewswire)
Mar-26-26 01:08PM	Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating (Investor's Business Daily)
Mar-23-26 08:30AM	TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus (GlobeNewswire)
Mar-06-26 10:22AM	Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating (Insider Monkey)
Mar-02-26 01:13PM	Maker Of Eye Drops Has Sights On Buy Point (Investor's Business Daily)
Feb-27-26 12:58PM	These Growth Stocks Form Classic Cup Bases. Here's Where To Buy. (Investor's Business Daily)
Feb-26-26 04:30PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-24-26 12:01AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2025 Earnings Call Highlights: Strong Financial ... (GuruFocus.com) +7.79%
Feb-23-26 08:17PM	Tarsus Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
07:25PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
07:17AM	Loading…
Feb-20-26 07:17AM	Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q4 2025 Result (GuruFocus.com)
Feb-18-26 10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
08:30AM	Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors (GlobeNewswire)
Feb-17-26 04:30PM	Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026 (GlobeNewswire)
10:00AM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-02-26 12:27PM	Will Declining Medical Customers Affect Cigna's Q4 Earnings? (Zacks)
Jan-26-26 09:35AM	Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS) (Zacks)
Jan-13-26 11:40AM	BMRN or TARS: Which Is the Better Value Stock Right Now? (Zacks)
Nov-24-25 04:30PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-05-25 05:05PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire)
12:04AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-04-25 05:55PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Nov-03-25 07:31AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-28-25 05:00PM	Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire)
Oct-09-25 09:27AM	Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains? (Zacks)
Oct-06-25 06:41AM	Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last? (Zacks)
Aug-27-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 06:33PM	3 Biotech Catalysts Present Major Opportunity (MarketBeat)
Aug-15-25 10:04AM	This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine (Investor's Business Daily)
Aug-14-25 02:48PM	Lyme Disease Is Spiking. This Biotech Nears A Treatment And A Buy Point. (Investor's Business Daily)
Aug-06-25 06:00PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +15.15%
04:05PM	Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-05-25 09:48AM	Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result (GuruFocus.com)
Jul-30-25 05:00PM	Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 (GlobeNewswire)
May-29-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 09:45AM	Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-08-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
May-05-25 06:04PM	Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts (Insider Monkey)
May-02-25 03:17AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2025 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com) -5.84%
May-01-25 09:37PM	Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Apr-30-25 10:17AM	Will Declining Medical Customers Affect Cigna's Q1 Earnings? (Zacks)
09:55AM	Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High? (Zacks)
Apr-25-25 10:00AM	Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline (Zacks)
Apr-24-25 05:00PM	Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 (GlobeNewswire)
11:00AM	Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? (Zacks)
Apr-23-25 01:41PM	HCA Healthcare to Report Q1 Earnings: Key Estimates to Note (Zacks)
Apr-22-25 11:19AM	Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch (Zacks)
08:31AM	Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting (GlobeNewswire)
Apr-21-25 04:05PM	Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders (Business Wire)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-20-25 09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-12-25 09:49PM	Tarsus Announces Pricing of Upsized $125.0 Million Public Offering (GlobeNewswire)
04:12PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Mar-06-25 05:00PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire) +6.66%
Feb-26-25 02:13AM	Q4 2024 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:05AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Feb-25-25 08:40AM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.33%
07:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
01:31AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-20-25 05:00PM	Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 (GlobeNewswire)
Jan-30-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-20-25 03:31PM	Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Jan-14-25 09:35AM	Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround (Zacks) -5.72%
Jan-13-25 08:30AM	Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care (GlobeNewswire) -10.76%
Dec-26-24 10:30AM	How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run (Investor's Business Daily)
Dec-04-24 09:55AM	Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet (Zacks)
Nov-18-24 09:55AM	Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade (Zacks)
Nov-14-24 02:15AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-13-24 05:30PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
08:30AM	Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors (GlobeNewswire)
Nov-07-24 10:00AM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Nov-06-24 04:30PM	Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 (GlobeNewswire)
Nov-05-24 08:30AM	Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer (GlobeNewswire)
Oct-30-24 06:39AM	Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LINK WILLIAM J PHD	Director	Sep 15 '26	Sale	78.38	12,500	979,744	94,487	Sep 17 04:22 PM
WILLIAM J LINK	DIRECTOR	Sep 15 '26	Proposed Sale	78.38	12,500	979,745		Sep 15 04:51 PM
Azamian Bobak R.	President/CEO and Board Chair	Sep 04 '26	Sale	90.56	10,000	905,600	827,991	Sep 09 04:14 PM
Lin Elizabeth Yeu	Chief Medical Officer	Sep 04 '26	Sale	87.50	10,773	942,635	2,547	Sep 09 04:13 PM
Lin Elizabeth Yeu	Chief Medical Officer	Sep 04 '26	Sale	87.50	3,180	278,250	1,590	Sep 09 04:13 PM
Neervannan Seshadri	Chief Operating Officer	Sep 04 '26	Sale	85.00	4,564	387,940	78,532	Sep 09 04:12 PM
BOBAK AZAMIAN	OFFICER	Sep 04 '26	Proposed Sale	90.56	10,000	905,587		Sep 04 05:23 PM
Lin Elizabeth Yeu	Member of immediate family of	Sep 04 '26	Proposed Sale	87.50	3,180	278,250		Sep 04 04:03 PM
Lin Elizabeth Yeu	Officer	Sep 04 '26	Proposed Sale	87.50	10,773	942,635		Sep 04 03:59 PM
Neervannan Seshadri	Officer	Sep 04 '26	Proposed Sale	85.00	4,564	387,940		Sep 04 03:36 PM
Lin Elizabeth Yeu	Chief Medical Officer	Sep 02 '26	Sale	80.00	5,387	430,960	13,320	Sep 03 04:29 PM
Lin Elizabeth Yeu	Chief Medical Officer	Sep 01 '26	Sale	73.86	4,601	339,830	18,707	Sep 03 04:29 PM
Lin Elizabeth Yeu	Chief Medical Officer	Sep 02 '26	Sale	80.00	1,590	127,200	4,770	Sep 03 04:29 PM
Lin Elizabeth Yeu	Member of immediate family of	Sep 02 '26	Proposed Sale	80.00	1,590	127,200		Sep 02 04:31 PM
Mottiwala Aziz	Former Officer	Sep 02 '26	Proposed Sale	81.80	8,000	654,373		Sep 02 03:40 PM
Lin Elizabeth Yeu	Officer	Sep 02 '26	Proposed Sale	80.00	5,387	430,960		Sep 02 03:38 PM
BOBAK AZAMIAN	OFFICER	Sep 02 '26	Proposed Sale	80.06	10,000	800,569		Sep 02 02:39 PM
Mottiwala Aziz	Former Officer	Sep 01 '26	Proposed Sale	73.96	77,698	5,746,846		Sep 01 04:09 PM
Lin Elizabeth Yeu	Officer	Sep 01 '26	Proposed Sale	73.86	4,601	339,830		Sep 01 02:23 PM
Mottiwala Aziz	Former Officer	Aug 25 '26	Proposed Sale	71.85	81,332	5,843,887		Aug 25 04:19 PM
Mottiwala Aziz	Former Officer	Aug 19 '26	Proposed Sale	72.00	53,043	3,819,096		Aug 19 02:27 PM
Azamian Bobak R.	President/CEO and Board Chair	Jun 17 '26	Sale	61.55	10,000	615,488	847,991	Jun 22 04:09 PM
Farrow Jeffrey S	See Remarks	Jun 16 '26	Sale	60.95	14,396	877,436	56,801	Jun 17 04:17 PM
Goodrich Katherine	Director	Jun 15 '26	Sale	62.08	2,954	183,384	2,233	Jun 17 04:17 PM
LINK WILLIAM J PHD	Director	Jun 15 '26	Sale	62.12	12,500	776,495	106,786	Jun 17 04:17 PM
BOBAK AZAMIAN	OFFICER	Jun 17 '26	Proposed Sale	61.55	10,000	615,473		Jun 17 02:05 PM
Farrow Jeffrey S	Officer	Jun 16 '26	Proposed Sale	60.95	14,396	877,459		Jun 16 04:53 PM
William J Link	Director	Jun 15 '26	Proposed Sale	62.12	12,500	776,498		Jun 15 04:58 PM
Goodrich Katherine	Director	Jun 15 '26	Proposed Sale	62.08	2,954	183,384		Jun 15 11:44 AM
Neervannan Seshadri	Chief Operating Officer	Mar 20 '26	Sale	66.75	2,989	199,516	82,791	Mar 24 05:05 PM
Neervannan Seshadri	Officer	Mar 20 '26	Proposed Sale	66.75	2,989	199,516		Mar 20 10:38 AM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 18 '26	Sale	68.71	4,071	279,718	39,202	Mar 19 07:04 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 17 '26	Sale	69.42	4,029	279,693	43,273	Mar 19 07:04 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 19 '26	Sale	67.00	4,174	279,658	35,028	Mar 19 07:04 PM
Wahl Bryan	General Counsel	Mar 17 '26	Sale	69.42	4,084	283,511	72,315	Mar 19 07:04 PM
Wahl Bryan	General Counsel	Mar 19 '26	Sale	67.00	4,231	283,477	63,959	Mar 19 07:04 PM
Wahl Bryan	General Counsel	Mar 18 '26	Sale	68.71	4,125	283,429	68,190	Mar 19 07:04 PM
Neervannan Seshadri	Chief Operating Officer	Mar 19 '26	Sale	67.00	4,589	307,463	85,780	Mar 19 07:04 PM
Neervannan Seshadri	Chief Operating Officer	Mar 18 '26	Sale	68.71	3,610	248,043	90,369	Mar 19 07:04 PM
Neervannan Seshadri	Chief Operating Officer	Mar 17 '26	Sale	69.42	3,125	216,938	93,979	Mar 19 07:04 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 17 '26	Sale	69.42	4,286	297,534	70,250	Mar 19 07:04 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 18 '26	Sale	68.71	4,330	297,514	65,920	Mar 19 07:04 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 19 '26	Sale	67.00	4,440	297,480	61,480	Mar 19 07:04 PM
Lin Elizabeth Yeu	Chief Medical Officer	Mar 19 '26	Sale	67.00	390	26,130	23,308	Mar 19 07:04 PM
Lin Elizabeth Yeu	Chief Medical Officer	Mar 18 '26	Sale	68.71	379	26,041	23,698	Mar 19 07:04 PM
Lin Elizabeth Yeu	Chief Medical Officer	Mar 17 '26	Sale	69.42	375	26,032	24,077	Mar 19 07:04 PM
Farrow Jeffrey S	See Remarks	Mar 18 '26	Sale	68.71	2,133	146,558	45,502	Mar 19 07:03 PM
Farrow Jeffrey S	See Remarks	Mar 17 '26	Sale	69.42	2,111	146,546	47,635	Mar 19 07:03 PM
Farrow Jeffrey S	See Remarks	Mar 19 '26	Sale	67.00	2,186	146,462	43,316	Mar 19 07:03 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 18 '26	Sale	68.71	11,667	801,640	45,385	Mar 19 07:03 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 19 '26	Sale	67.00	11,964	801,588	33,421	Mar 19 07:03 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 17 '26	Sale	69.42	10,972	761,676	57,052	Mar 19 07:03 PM
Farrow Jeffrey S	Officer	Mar 19 '26	Proposed Sale	67.00	2,186	146,459		Mar 19 04:43 PM
Mottiwala Aziz	Officer	Mar 19 '26	Proposed Sale	67.00	4,440	297,475		Mar 19 04:38 PM
Azamian Bobak R.	Officer	Mar 19 '26	Proposed Sale	67.00	11,964	801,574		Mar 19 04:30 PM
Whitfield Dianne C.	Officer	Mar 19 '26	Proposed Sale	67.00	4,174	279,653		Mar 19 04:24 PM
Wahl Bryan	Officer	Mar 19 '26	Proposed Sale	67.00	4,231	283,472		Mar 19 04:23 PM
Neervannan Seshadri	Officer	Mar 19 '26	Proposed Sale	67.00	4,589	307,457		Mar 19 04:15 PM
Lin Elizabeth Yeu	Officer	Mar 19 '26	Proposed Sale	67.00	390	26,130		Mar 19 04:14 PM
Whitfield Dianne C.	Officer	Mar 18 '26	Proposed Sale	68.71	4,071	279,718		Mar 18 04:33 PM
Wahl Bryan	Officer	Mar 18 '26	Proposed Sale	68.71	4,125	283,428		Mar 18 04:18 PM
Azamian Bobak R.	Officer	Mar 18 '26	Proposed Sale	68.71	11,667	801,637		Mar 18 04:17 PM
Neervannan Seshadri	Officer	Mar 18 '26	Proposed Sale	68.71	3,610	248,042		Mar 18 04:17 PM
Farrow Jeffrey S	Officer	Mar 18 '26	Proposed Sale	68.71	2,133	146,558		Mar 18 04:14 PM
Mottiwala Aziz	Officer	Mar 18 '26	Proposed Sale	68.71	4,330	297,513		Mar 18 04:13 PM
Lin Elizabeth Yeu	Officer	Mar 18 '26	Proposed Sale	68.71	379	26,041		Mar 18 04:11 PM
LINK WILLIAM J PHD	Director	Mar 16 '26	Sale	68.79	12,500	859,819	116,332	Mar 18 04:11 PM
Azamian Bobak R.	Officer	Mar 17 '26	Proposed Sale	69.41	10,972	761,618		Mar 17 04:09 PM
Neervannan Seshadri	Officer	Mar 17 '26	Proposed Sale	69.41	3,125	216,921		Mar 17 04:07 PM
Farrow Jeffrey S	Officer	Mar 17 '26	Proposed Sale	69.41	2,111	146,534		Mar 17 04:03 PM
Wahl Bryan	Officer	Mar 17 '26	Proposed Sale	69.41	4,084	283,490		Mar 17 03:59 PM
Whitfield Dianne C.	Officer	Mar 17 '26	Proposed Sale	69.41	4,029	279,672		Mar 17 03:55 PM
Lin Elizabeth Yeu	Officer	Mar 17 '26	Proposed Sale	69.41	375	26,031		Mar 17 03:47 PM
Mottiwala Aziz	Officer	Mar 17 '26	Proposed Sale	69.41	4,286	297,511		Mar 17 03:42 PM
WILLIAM J LINK	DIRECTOR	Mar 16 '26	Proposed Sale	68.78	12,500	859,787		Mar 16 05:39 PM
Neervannan Seshadri	Chief Operating Officer	Mar 04 '26	Sale	76.67	8,366	641,421	70,817	Mar 05 04:03 PM
Neervannan Seshadri	Officer	Mar 04 '26	Proposed Sale	76.67	8,366	641,421		Mar 04 10:56 AM
Whitfield Dianne C.	Chief Human Resources Officer	Jan 02 '26	Sale	80.67	15,565	1,255,684	23,393	Jan 06 04:05 PM
Whitfield Dianne C.	Officer	Jan 02 '26	Proposed Sale	81.38	15,565	1,266,680		Jan 02 11:22 AM
Azamian Bobak R.	President/CEO and Board Chair	Dec 24 '25	Sale	82.51	6,000	495,089	857,991	Dec 30 04:26 PM
BOBAK AZAMIAN	OFFICER	Dec 24 '25	Proposed Sale	82.51	6,000	495,089		Dec 29 12:22 PM
Whitfield Dianne C.	Chief Human Resources Officer	Dec 16 '25	Sale	80.10	7,397	592,500	38,958	Dec 18 04:09 PM
LINK WILLIAM J PHD	Director	Dec 15 '25	Sale	81.43	12,500	1,017,816	128,832	Dec 17 04:07 PM
LINK WILLIAM J PHD	Director	Dec 15 '25	Sale	81.07	10,446	846,862	0	Dec 17 04:07 PM
Lin Elizabeth Yeu	Chief Medical Officer	Dec 16 '25	Sale	79.50	2,078	165,201	21,941	Dec 17 04:07 PM
Lin Elizabeth Yeu	Officer	Dec 16 '25	Proposed Sale	79.50	2,078	165,202		Dec 16 03:12 PM
Whitfield Dianne C.	Officer	Dec 16 '25	Proposed Sale	80.10	7,397	592,500		Dec 16 10:11 AM
William Link	Director	Dec 15 '25	Proposed Sale	81.02	10,446	846,340		Dec 15 04:38 PM
WILLIAM J LINK	DIRECTOR	Dec 15 '25	Proposed Sale	81.42	12,500	1,017,800		Dec 15 04:08 PM

Tarsus Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Co-FounderDr. Bobak R. Azamian M.D.

Chief Operating OfficerDr. Seshadri Neervannan Ph.D.

M.D.Dr. Bryan Wahl J.D.

Head of Investor RelationsMr. David Nakasone

Vice President of Corporate CommunicationsMs. Adrienne Kemp

Open in Screener

PASG

Passage Bio Inc

3.37

Oct 23 • 3:59 PM ET -0.14 (-3.99%)

3.40

Aftermarket • 4:15 PM ET +0.03 (0.89%)

Healthcare Biotechnology USA Nano NASD

Peers: TSHA ALEC VYGR LXEO NGNE QURE MGTX DNLI ABEO SLDB

| Held by: VTI VXF

Index	-
Market Cap	10.85M
Enterprise Value	-13.31M
Income	-36.11M
Sales	0.00M
Book/sh	1.38
Cash/sh	7.50
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	24
IPO	Feb 28, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.43
P/C	0.45
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.22
Current Ratio	1.22
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-11.31
EPS next Y	-10.20
EPS next Q	-2.44
EPS this Y	31.85%
EPS next Y	-4.29%
EPS next 5Y	-
EPS past 3/5Y	34.05% 24.41%
Sales past 3/5Y	- -
EPS Y/Y TTM	38.14%
Sales Y/Y TTM	-
EPS Q/Q	17.70%
Sales Q/Q	-
Earnings	Jul 30
EPS/Sales Surpr.	-7.49% -

Insider Own	7.71%
Insider Trans	25.29%
Inst Own	43.75%
Inst Trans	-4.51%
ROA	-69.20%
ROE	-169.09%
ROIC	-810.41%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-13.83%
SMA50	-23.17%
SMA200	-48.88%
Trades

Shs Outstand	3.22M
Shs Float	2.97M
Short Float	3.06%
Short Ratio	4.30
Short Interest	0.09M
52W High	20.00 -83.15%
52W Low	3.29 2.43%
Volatility	7.26% 9.22%
ATR (14)	0.33
RSI (14)	33.86
Beta	1.49
Rel Volume	1.02
Avg Volume	21.10K
Volume	21,535

Perf Week	-3.71%
Perf Month	-29.79%
Perf Quarter	-27.06%
Perf Half Y	-42.29%
Perf YTD	-71.44%
Perf Year	-54.64%
Perf 3Y	-74.81%
Perf 5Y	-98.11%
Perf 10Y	-
Recom	2.33
Target Price	15.50
Prev Close	3.51
Price	3.37
Change %	-3.99%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-10-26	Downgrade	Guggenheim	Buy → Neutral
Apr-21-26	Downgrade	Wedbush	Outperform → Neutral	$8
Apr-21-26	Downgrade	TD Cowen	Buy → Hold
Apr-21-26	Downgrade	Chardan Capital Markets	Buy → Neutral	$7
Mar-31-26	Initiated	Oppenheimer	Outperform	$30
Feb-10-26	Resumed	Chardan Capital Markets	Buy	$21
Nov-29-24	Resumed	Wedbush	Outperform	$3 → $4
Sep-03-24	Initiated	Rodman & Renshaw	Buy	$7
Mar-08-22	Downgrade	JP Morgan	Overweight → Neutral
Jan-19-22	Downgrade	Goldman	Buy → Neutral	$29 → $6
Jul-01-21	Initiated	Raymond James	Outperform	$29
Jun-15-21	Initiated	BTIG Research	Buy	$25
Mar-04-21	Upgrade	Goldman	Neutral → Buy	$28 → $30
Feb-04-21	Initiated	Guggenheim	Buy	$25
Jan-25-21	Initiated	Wedbush	Outperform	$26
Jan-04-21	Upgrade	JP Morgan	Neutral → Overweight	$25 → $35
Dec-11-20	Initiated	Citigroup	Neutral	$28
Aug-14-20	Downgrade	JP Morgan	Overweight → Neutral	$25
Jun-25-20	Downgrade	Goldman	Buy → Neutral	$28
Mar-25-20	Initiated	Chardan Capital Markets	Buy	$30

Show Previous Ratings

Jun-25-26 06:55AM	Remix to go public in reverse merger with once high-flying Passage Bio (BioPharma Dive) -26.36%
Jun-24-26 09:43PM	SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today (Stocktwits)
06:47PM	PASG Stock Slumps 16% After-Hours Whats Driving The Selloff? (Stocktwits)
04:05PM	Passage Bio and Remix Therapeutics Announce Merger Agreement (GlobeNewswire)
Apr-21-26 10:03AM	Intel upgraded, Reddit initiated: Wall Street's top analyst calls (The Fly)
07:00AM	Loading…
Apr-20-26 07:00AM	Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates (GlobeNewswire) -46.44%
Mar-03-26 07:00AM	Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -8.88%
Feb-19-26 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-10-25 04:15PM	Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire) +6.68% +14.84%
Nov-05-25 07:00AM	Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Oct-14-25 07:00AM	Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-01-25 09:55AM	Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet (Zacks)
Aug-28-25 07:00AM	Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-15-25 09:55AM	Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade (Zacks) -8.43%
09:25AM	Passage Bio price target lowered to $67 from $260 at Canaccord (TipRanks)
07:00AM	Loading…
Aug-12-25 07:00AM	Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Jul-10-25 07:00AM	Passage Bio Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -9.86%
Jun-23-25 07:00AM	Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update (GlobeNewswire) -14.37%
May-13-25 07:00AM	Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-07-25 12:00PM	Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-04-25 07:00AM	Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -11.37%
Feb-26-25 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-10-25 07:00AM	Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates (GlobeNewswire)
Nov-30-24 06:55AM	Passage Bio assumed with an Outperform at Wedbush (TipRanks)
Nov-14-24 07:29AM	Passage Bio Achieves Milestones in Gene Therapy Trials (TipRanks)
Nov-13-24 07:00AM	Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -12.87%
Nov-06-24 07:00AM	Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Oct-24-24 07:00AM	Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference (GlobeNewswire) +11.40%
Sep-23-24 09:36PM	Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc (GuruFocus.com) -5.11%
07:00AM	Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
01:25AM	Loading…
Sep-19-24 01:25AM	Orbimed Advisors LLC Reduces Stake in Passage Bio Inc (GuruFocus.com)
Sep-16-24 07:00AM	Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024) (GlobeNewswire) -9.45%
Sep-10-24 07:52AM	Passage Bio Welcomes Tom Kassberg to Board of Directors (GlobeNewswire) +6.06%
Aug-30-24 07:00AM	Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.96%
Aug-08-24 07:00AM	Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -5.22%
Aug-06-24 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 12:30PM	Jim Wilson, prominent gene therapy researcher, to depart UPenn (BioPharma Dive) +6.63%
07:00AM	Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration (GlobeNewswire)
Jul-25-24 07:13AM	Passage Bio targets FDA to greenlight ALS gene therapy trial (Clinical Trials Arena) +6.23%
Jul-16-24 07:43AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients (GlobeNewswire)
Jun-18-24 09:35AM	Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.45%
Jun-05-24 07:30AM	Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-21-24 08:00AM	Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award (GlobeNewswire)
May-16-24 12:00PM	All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy (Zacks)
May-14-24 01:54PM	PASG Stock Earnings: Passage Bio Beats EPS for Q1 2024 (InvestorPlace) -10.47%
07:00AM	Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Apr-22-24 07:00AM	Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-07-24 12:00PM	Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know (Zacks) -6.43%
Mar-06-24 01:52PM	PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023 (InvestorPlace)
Mar-05-24 07:00AM	Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program (GlobeNewswire)
Mar-04-24 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Feb-27-24 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.12%
Feb-01-24 07:09PM	7 Analyst-Backed Stocks With Promising 10-Bagger Potential (InvestorPlace) +5.13%
Jan-31-24 07:30AM	Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-25-23 10:14PM	7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight (InvestorPlace)
Dec-20-23 07:00AM	Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities (GlobeNewswire) +7.35%
Nov-17-23 04:30PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-13-23 07:00AM	Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Oct-30-23 07:00AM	Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference (GlobeNewswire) +6.91%
Oct-20-23 04:30PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-25-23 07:00AM	Passage Bio to Present at Chardans 7th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-11-23 10:04AM	Lab Notes: Almac Group starts work on $65M Montco expansion expected to create 355 jobs (American City Business Journals)
Aug-07-23 07:15AM	Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -5.11%
07:00AM	Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study (GlobeNewswire)
Aug-01-23 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-31-23 07:00AM	Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors (GlobeNewswire)
Jul-24-23 12:37PM	Passage Bio reduces staff by 26% in latest round of job cuts (American City Business Journals) -5.31%
Jul-06-23 11:17AM	12 Best Nano Cap Stocks To Buy Now (Insider Monkey)
Jun-05-23 07:00AM	Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-11-23 07:00AM	Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
May-04-23 07:00AM	Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award (GlobeNewswire) +5.91%
Apr-21-23 04:01PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-17-23 07:00AM	Passage Bio to Present at Chardans 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-29-23 09:02AM	Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-27-23 07:00AM	Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-08-23 07:14AM	Passage Bio, Inc. (NASDAQ:PASG) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 12:42AM	Q4 2022 Passage Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-06-23 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-01-23 07:00AM	Passage Bio Seeks Pennsylvania College Student Candidates for Second Annual Tachi Yamada Scholarship Program (GlobeNewswire)
Feb-28-23 07:00AM	Passage Bio to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-27-23 07:00AM	Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023 (GlobeNewswire) +7.69%
Feb-24-23 07:00AM	Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 (GlobeNewswire) -7.87%
Feb-20-23 05:59PM	'We've turned the page': CEO says Passage Bio is building momentum after turbulent 2022 (American City Business Journals)
Feb-15-23 07:00AM	Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 (GlobeNewswire)
Jan-20-23 04:01PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-23 07:39AM	After losing 67% in the past year, Passage Bio, Inc. (NASDAQ:PASG) institutional owners must be relieved by the recent gain (Simply Wall St.)
Dec-14-22 12:13PM	Passage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage Disorder (Benzinga) +9.65%
07:00AM	Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study (GlobeNewswire)
Nov-21-22 05:24AM	Estimating The Fair Value Of Passage Bio, Inc. (NASDAQ:PASG) (Simply Wall St.)
Nov-10-22 07:00AM	Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +10.83%
Nov-08-22 07:00AM	Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day (GlobeNewswire)
Nov-03-22 07:30AM	Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022 (GlobeNewswire)
Oct-14-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.88%
Oct-11-22 12:25PM	Here's Why Passage Bio (NASDAQ:PASG) Must Use Its Cash Wisely (Simply Wall St.)
Oct-10-22 07:00AM	Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer (GlobeNewswire)
Sep-26-22 07:00AM	Passage Bio to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-19-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-11-22 07:00AM	Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations (GlobeNewswire)
Aug-05-22 07:00AM	Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynx1 Capital Management LP	10% Owner	Jun 25 '26	Buy	4.12	50,055	206,101	673,759	Jun 29 04:30 PM
Chou William	PRESIDENT AND CEO	Jan 08 '26	Sale	18.44	4,076	75,159	6,524	Jan 12 04:03 PM
Borthwick Kathleen	CFO	Jan 08 '26	Sale	18.44	2,062	38,022	5,402	Jan 12 04:03 PM
Chou William	Officer	Jan 09 '26	Proposed Sale	18.43	4,076	75,120		Jan 09 04:03 PM

Passage Bio, Inc. operates as a genetic medicines company. It focuses on development of therapies for central nervous system disorders. The company was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Ph.D.Dr. William Chou M.D.

Senior VPMs. Kathleen Borthwick

Open in Screener

PHAT

Phathom Pharmaceuticals Inc

5.74

Oct 23 • 3:59 PM ET -1.27 (-18.12%)

5.72

Aftermarket • 7:30 PM ET -0.02 (-0.35%)

Healthcare Biotechnology USA Small NASD

PHAT Phathom Pharmaceuticals Inc daily Stock Chart

Peers: ARDX IRWD RIGL TAK BHC HRMY COLL EOLS AQST SUPN

| Held by: VTI IWM VXF XPH IBB IWN SCHA VTWO SURI IHE

Index	RUT
Market Cap	464.37M
Enterprise Value	833.91M
Income	-99.07M
Sales	239.66M
Book/sh	-4.30
Cash/sh	2.26
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	371
IPO	Oct 25, 2019

P/E	-
Forward P/E	8.01
PEG	-
P/S	1.94
P/B	-
P/C	2.54
P/FCF	-
EV/EBITDA	-
EV/Sales	3.48
Quick Ratio	1.87
Current Ratio	1.92
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.27
EPS next Y	0.72
EPS next Q	-0.11
EPS this Y	76.20%
EPS next Y	199.43%
EPS next 5Y	-
EPS past 3/5Y	15.64% 4.82%
Sales past 3/5Y	- -
EPS Y/Y TTM	73.04%
Sales Y/Y TTM	110.16%
EPS Q/Q	79.93%
Sales Q/Q	88.02%
Earnings	Oct 29 BMO
EPS/Sales Surpr.	-19.59% 1.42%

Insider Own	36.68%
Insider Trans	0.00%
Inst Own	60.01%
Inst Trans	7.29%
ROA	-34.32%
ROE	-
ROIC	-58.35%
Gross Margin	82.92%
Oper. Margin	-16.96%
Profit Margin	-41.34%
SMA20	-18.43%
SMA50	-27.87%
SMA200	-46.20%
Trades

Shs Outstand	80.07M
Shs Float	51.23M
Short Float	19.73%
Short Ratio	7.31
Short Interest	10.11M
52W High	18.31 -68.65%
52W Low	6.52 -11.96%
Volatility	11.09% 6.83%
ATR (14)	0.53
RSI (14)	29.51
Beta	0.66
Rel Volume	3.52
Avg Volume	1.38M
Volume	4,868,148

Perf Week	-17.05%
Perf Month	-18.93%
Perf Quarter	-51.97%
Perf Half Y	-50.94%
Perf YTD	-65.40%
Perf Year	-57.83%
Perf 3Y	-38.74%
Perf 5Y	-80.34%
Perf 10Y	-
Recom	1.45
Target Price	19.64
Prev Close	7.01
Price	5.74
Change %	-18.12%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-26	Initiated	Leerink Partners	Market Perform	$10
Mar-27-26	Upgrade	Barclays	Equal Weight → Overweight	$18
Dec-12-25	Initiated	Raymond James	Strong Buy	$28
Dec-09-25	Initiated	Barclays	Equal Weight	$16
Feb-14-25	Initiated	Cantor Fitzgerald	Overweight	$23
May-03-24	Initiated	Stifel	Buy	$24
Jan-05-24	Reiterated	Needham	Buy	$23 → $26
Aug-09-23	Initiated	H.C. Wainwright	Buy	$28
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy	$21
Oct-21-22	Initiated	Jefferies	Buy	$16
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral	$40 → $48
Feb-17-21	Initiated	BMO Capital Markets	Outperform	$63
Feb-02-21	Initiated	Guggenheim	Buy	$60
Jun-26-20	Downgrade	Goldman	Neutral → Sell	$34
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Needham	Buy	$40
Nov-19-19	Initiated	Jefferies	Buy	$32
Nov-19-19	Initiated	Goldman	Neutral	$32

Show Previous Ratings

Oct-23-26 01:45PM	PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drugs Exclusivity (Stocktwits) -18.12%
04:00AM	Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA (GlobeNewswire)
Oct-21-26 01:38PM	Phathom's Prescribing Friction Faces Its First Test After Guidance Cut Rattled Investors (Earnings Whispers)
Oct-19-26 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026 (GlobeNewswire)
Oct-12-26 08:00AM	Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA (vonoprazan) at ACG 2026 (GlobeNewswire)
08:00AM	Loading…
Oct-08-26 08:00AM	Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting (GlobeNewswire)
Sep-29-26 08:00AM	Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA (vonoprazan) for As-Needed Treatment of Non-Erosive GERD (GlobeNewswire)
Sep-09-26 01:26PM	PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside CEO Plays Down Upcoming Rival (Stocktwits) -8.06%
Sep-01-26 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-30-26 06:09PM	PHAT Stock Clocks Worst Day In Over 1.5 Years What Sparked The Selloff? (Stocktwits) -22.42%
03:01PM	Phathom Pharmaceuticals Inc (PHAT) (Q2 2026) Earnings Call Highlights: First Positive Operating ... (GuruFocus.com)
06:59AM	Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-26 09:58AM	Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q2 2026 Result (GuruFocus.com)
Jul-20-26 08:00AM	Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026 (GlobeNewswire)
Jun-23-26 07:59AM	Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA (vonoprazan) in Eosinophilic Esophagitis (EoE) (GlobeNewswire)
08:00AM	Loading…
May-22-26 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-20-26 08:00AM	Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting (GlobeNewswire)
May-01-26 08:00AM	Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at DDW 2026 Annual Meeting (GlobeNewswire) +7.23%
Apr-30-26 06:59AM	Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-26 09:24AM	Phathom Pharmaceuticals Inc (PHAT) Q1 2026: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Apr-20-26 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026 (GlobeNewswire)
Apr-06-26 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-01-26 04:27AM	Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why (Insider Monkey)
Feb-27-26 04:30AM	Phathom Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) -7.37%
Feb-26-26 04:12PM	Phathom Pharmaceuticals Inc (PHAT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +10.06%
12:15PM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance (GlobeNewswire)
Feb-25-26 07:33AM	What To Expect From Phathom Pharmaceuticals Inc (PHAT) Q4 2025 Earnings (GuruFocus.com) +6.12%
Feb-24-26 09:40AM	Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-23-26 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Loading…
Feb-17-26 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 (GlobeNewswire) +6.16%
Feb-14-26 05:05PM	Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit (MarketBeat)
Feb-05-26 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 (GlobeNewswire) -6.20%
Jan-08-26 08:49AM	Phathom's Early Numbers Show Sales Strength, Eyes 2026 Profitability (Benzinga) -13.72%
05:17AM	Stock Market Today: S&P 500, Dow Jones Futures Decline - AZZ, Northrop Grumman, Immuneering In Focus (Benzinga)
Jan-07-26 10:33PM	Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +10.45%
04:05PM	Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:01PM	Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Dec-25-25 07:00PM	Raymond James Sees an Attractive Setup in These 2 Strong Buy Stocks (TipRanks)
Nov-04-25 08:00AM	Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA (vonoprazan) in Eosinophilic Esophagitis (EoE) (GlobeNewswire)
Nov-03-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-25 04:24PM	Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-29-25 09:49AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-25-25 09:59AM	Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease (GlobeNewswire)
Oct-23-25 08:00AM	Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting (GlobeNewswire)
Oct-20-25 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 (GlobeNewswire) +8.10%
Oct-06-25 08:00AM	Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer (GlobeNewswire)
Sep-18-25 12:00PM	Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why (Zacks) +6.82%
Sep-08-25 05:04PM	Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High? (Zacks)
Aug-25-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-22-25 09:55AM	Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet (Zacks) +8.77%
Aug-20-25 08:00AM	Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing (GlobeNewswire)
Aug-07-25 08:10AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.29%
06:59AM	Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-25 08:25AM	MannKind (MNKD) Reports Break-Even Earnings for Q2 (Zacks)
Aug-04-25 08:15AM	Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-28-25 08:00AM	Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 (GlobeNewswire) -8.62%
Jun-23-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.12%
07:59AM	Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Jun-16-25 08:00AM	Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets Through May 3, 2032 (GlobeNewswire)
Jun-09-25 09:55AM	Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade (Zacks)
Jun-06-25 12:45PM	Phathom Pharmaceuticals shares soar on FDA exclusivity grant (Investing.com) +90.19%
12:27PM	Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032 (GlobeNewswire)
May-15-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.08%
May-08-25 09:35AM	After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT) (Zacks)
May-02-25 03:02AM	Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com) -17.86%
May-01-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -21.68%
12:09PM	Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 07:59AM	Phathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2025 Annual Meeting (GlobeNewswire)
Apr-23-25 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 (GlobeNewswire)
Apr-16-25 08:00AM	Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors (GlobeNewswire) -11.43%
Apr-08-25 07:09AM	Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? (Zacks) -12.73%
Apr-03-25 11:25AM	Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade) (Seeking Alpha) -8.83%
08:00AM	Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -18.34% +7.23%
08:00AM	Phathom Pharmaceuticals Announces Leadership Succession (GlobeNewswire)
Mar-31-25 07:59AM	Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA (vonoprazan) (GlobeNewswire)
Mar-07-25 02:08AM	Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ... (GuruFocus.com) -14.24%
Mar-06-25 09:10AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-25 07:21AM	Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result (GuruFocus.com) +8.96%
Feb-24-25 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 (GlobeNewswire) -5.82%
Jan-29-25 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Dec-12-24 09:39AM	Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)? (Insider Monkey)
Dec-11-24 08:00AM	Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA (vonoprazan) Tablets (GlobeNewswire) -5.99%
Dec-06-24 09:35AM	Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround (Zacks) +5.88%
Nov-19-24 12:00PM	Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know (Zacks) +5.40%
Nov-08-24 06:02AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -8.86%
Nov-07-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-24 07:21AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Nov-04-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 (GlobeNewswire) +8.29%
Oct-27-24 12:00PM	Phathom Pharmaceuticals to Present VOQUEZNA Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting (GlobeNewswire)
Aug-29-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-24 08:00AM	Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parikh Asit	Director	May 20 '26	Option Exercise	4.95	17,500	86,625	52,122	May 21 05:16 PM
Parikh Asit	Director	Jan 13 '26	Option Exercise	10.30	8,750	90,125	131,000	Jan 15 04:45 PM
Parikh Asit	Director	Dec 19 '25	Option Exercise	10.30	8,750	90,125	122,250	Dec 23 05:00 PM
Basta Steven L	President and CEO	Nov 28 '25	Option Exercise	0.00	90,000	0	131,625	Dec 02 06:45 PM
Breedlove Robert Charles	Principal Accounting Officer	Nov 03 '25	Sale	13.51	524	7,079	47,407	Nov 05 04:30 PM

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

CEOMr. Steven L. Basta M.B.A.

Co-FounderMr. David A. Socks

M.P.H.Dr. Azmi Nabulsi M.D.

Chief Financial & Business OfficerMr. Sanjeev Narula

J.D.Ms. Anne Marie Cook Esq.

Open in Screener

MIRM

Mirum Pharmaceuticals Inc

80.39

Oct 23 • 3:59 PM ET -2.71 (-3.26%)

80.39

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

MIRM Mirum Pharmaceuticals Inc daily Stock Chart

Peers: MDGL VIR TVTX PTCT RYTM RARE IVA GILD ZVRA BCRX

| Held by: VTI XBI VB IWM VBK VXF IWO IBB SCHA VTWO

Index	RUT
Market Cap	5.22B
Enterprise Value	5.54B
Income	-860.21M
Sales	618.07M
Book/sh	-0.16
Cash/sh	6.75
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	372
IPO	Jul 18, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	8.45
P/B	-
P/C	11.91
P/FCF	-
EV/EBITDA	-
EV/Sales	8.97
Quick Ratio	2.74
Current Ratio	2.86
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-14.55
EPS next Y	-0.63
EPS next Q	-0.49
EPS this Y	-3117.62%
EPS next Y	95.81%
EPS next 5Y	-
EPS past 3/5Y	51.26% 35.25%
Sales past 3/5Y	89.13% -
EPS Y/Y TTM	-1101.02%
Sales Y/Y TTM	44.02%
EPS Q/Q	-799.75%
Sales Q/Q	37.92%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	-42.76% 5.93%

Insider Own	17.16%
Insider Trans	-1.59%
Inst Own	94.66%
Inst Trans	4.48%
ROA	-97.15%
ROE	-702.97%
ROIC	-114.68%
Gross Margin	81.65%
Oper. Margin	-14.76%
Profit Margin	-139.18%
SMA20	-3.08%
SMA50	-12.07%
SMA200	-18.50%
Trades

Shs Outstand	64.75M
Shs Float	53.79M
Short Float	12.99%
Short Ratio	9.59
Short Interest	6.99M
52W High	130.00 -38.16%
52W Low	63.23 27.13%
Volatility	3.38% 4.68%
ATR (14)	3.76
RSI (14)	39.32
Beta	0.76
Rel Volume	1.08
Avg Volume	728.16K
Volume	788,241

Perf Week	0.31%
Perf Month	-10.04%
Perf Quarter	-29.61%
Perf Half Y	-12.13%
Perf YTD	1.77%
Perf Year	15.82%
Perf 3Y	188.24%
Perf 5Y	428.53%
Perf 10Y	-
Recom	1.07
Target Price	153.43
Prev Close	83.10
Price	80.39
Change %	-3.26%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-26	Initiated	Citigroup	Buy	$145
May-19-26	Initiated	Wolfe Research	Outperform	$145
Feb-18-26	Initiated	RBC Capital Mkts	Outperform	$130
Sep-24-25	Initiated	TD Cowen	Buy	$95
Aug-11-25	Resumed	Stifel	Buy	$89
May-19-25	Resumed	H.C. Wainwright	Buy	$73
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33

Show Previous Ratings

Oct-21-26 04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Oct-15-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-12-26 11:48AM	Mirum tees up Livmarli label expansion on Phase III liver disease study success (Clinical Trials Arena)
10:00AM	Mirum gains as Phase 3 LIVMARLI trial meets primary endpoint in liver disease (Investing.com)
08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Ultra-Rare Cholestatic Liver Diseases (Business Wire)
05:00PM	Loading…
Oct-11-26 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Ultra-Rare Cholestatic Liver Diseases (Business Wire)
Sep-30-26 10:18AM	PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval (BioPharma Dive)
Sep-28-26 08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus (Business Wire)
06:44AM	FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals (Stocktwits)
Sep-27-26 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 (Business Wire)
Sep-25-26 07:00PM	Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva (Business Wire)
02:43PM	INCY, MIRM Slip Into FDAs Weekend Decision Date On Shared Rare-Disease Pill (Stocktwits)
Sep-21-26 07:06AM	FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week (Stocktwits)
Sep-17-26 06:44PM	MIRM, INCY Stocks In Focus Will A September 26 FDA Ruling Reward This Weeks Gains? (Stocktwits) -7.07%
Sep-14-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Loading…
Sep-08-26 08:30AM	Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer (Business Wire)
Sep-02-26 04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-11-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-06-26 09:46AM	Citizens Says FDAs 'Unexpected' Phase 3 Request Clouds Mirums Near-Term Outlook MIRM Stock Crashes 15% (Stocktwits) -11.04%
Aug-05-26 04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update (Business Wire)
Jul-29-26 04:01PM	Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 (Business Wire)
Jul-13-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-14-26 04:35PM	Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva (Business Wire)
Jun-11-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.89%
Jun-04-26 08:05AM	Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 (Business Wire)
May-30-26 12:00PM	Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 (Business Wire)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com)
May-21-26 08:05AM	Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026 (Business Wire)
May-14-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.26%
May-12-26 11:56PM	Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes (Business Wire)
04:01PM	Loading…
04:01PM	Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering (Business Wire)
08:00AM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-06-26 04:01PM	Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire) -6.50%
May-05-26 08:59AM	Idexx Claws Down A Beat As Shares Bound Higher On A Guidance Hike (Investor's Business Daily)
May-04-26 12:59PM	Why This Biotech ETF - The IBD Stock Of The Day - Just Reentered Its Buy Zone (Investor's Business Daily) +9.59%
12:05PM	The $1 Billion-Plus Opportunity That Sent Mirum Pharma Catapulting To A Record (Investor's Business Daily)
08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis (Business Wire)
May-03-26 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 (Business Wire)
Apr-29-26 04:01PM	Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 (Business Wire)
Apr-27-26 08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus (Business Wire)
Mar-16-26 08:00AM	Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Additional Rare Cholestatic Liver Diseases (Business Wire)
Mar-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-06-26 08:27AM	Mirum Completes Enrollment & Screening in Liver Disease Studies (Zacks)
Mar-05-26 08:00AM	Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus (Business Wire) -5.59%
Feb-26-26 10:50AM	Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues (Zacks) -15.13%
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Feb-25-26 08:00PM	Mirum Pharmaceuticals (MIRM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:25PM	Mirum Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update (Business Wire)
Feb-23-26 07:25PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
Feb-19-26 06:03AM	ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last? (Zacks)
Feb-18-26 04:01PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
Feb-10-26 10:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-05-26 08:51AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Business Wire) -5.51%
08:00AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) (Business Wire)
Feb-03-26 02:10AM	Mirum doubles down on diversified rare disease strategy (Pharma Voice)
Jan-31-26 03:22PM	Is Mirum Pharmaceuticals on a Strong Path to Profitability? (Motley Fool)
08:15AM	Insiders Are Still Scooping Up Under Armour and WR Berkley Shares (24/7 Wall St.)
Jan-29-26 02:27PM	H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? (Insider Monkey)
Jan-27-26 06:33AM	Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline (Pharmaceutical Technology)
03:15AM	Is Mirum Pharmaceuticals About to Soar in 2026? (Motley Fool)
Jan-26-26 08:00AM	Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Jan-22-26 09:52PM	Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results (Insider Monkey)
Jan-20-26 09:38AM	CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? (Zacks)
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-13-26 05:04AM	3 Top Growth Stocks to Buy in the First Half of 2026 (Motley Fool)
Jan-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum (Business Wire)
Jan-09-26 11:55AM	Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals (Business Wire) +6.09%
Jan-07-26 04:01PM	Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.22%
Jan-06-26 08:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-04-26 04:05AM	5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right (Motley Fool)
Dec-30-25 03:07AM	Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now (Motley Fool)
Dec-23-25 01:52PM	This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone (Investor's Business Daily)
Dec-19-25 08:30AM	Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX (Business Wire) +10.61%
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 07:44AM	Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition (Insider Monkey)
Dec-09-25 09:45AM	Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald (TipRanks)
09:42AM	Mirum to buy Bluejay for up to $820m in rare liver disease push (Pharmaceutical Technology)
Dec-08-25 08:31AM	Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay (BioPharma Dive)
08:00AM	Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Dec-04-25 11:30AM	Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-03-25 06:30AM	Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 (Motley Fool)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
Dec-01-25 08:10AM	Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-25-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-25 08:10AM	Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire)
Nov-05-25 11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-04-25 05:10PM	Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Howe Jolanda	SVP, GLOBAL CONTROLLER	Oct 16 '26	Option Exercise	19.24	16,112	309,995	16,728	Oct 19 04:10 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Oct 06 '26	Option Exercise	17.31	12,197	211,179	206,637	Oct 06 08:38 PM
ERIC BJERKHOLT	Officer	Sep 14 '26	Proposed Sale	98.37	9,943	978,093		Sep 15 04:18 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Sep 14 '26	Sale	98.37	9,943	978,093	44,745	Sep 15 04:10 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Sep 02 '26	Sale	100.00	658	65,800	616	Sep 03 06:54 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Sep 01 '26	Option Exercise	2.94	30,000	88,080	224,440	Sep 03 06:52 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Sep 01 '26	Sale	98.68	30,000	2,960,401	194,440	Sep 03 06:52 PM
JOLANDA MARIE HOWE	Officer	Sep 02 '26	Proposed Sale	100.00	658	65,800		Sep 02 04:06 PM
CHRISTOPHER PEETZ	Officer	Sep 01 '26	Proposed Sale	98.68	30,000	2,960,319		Sep 01 04:12 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 18 '26	Option Exercise	6.27	40,000	250,800	41,274	Aug 19 06:19 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 18 '26	Sale	100.00	40,000	4,000,000	1,274	Aug 19 06:19 PM
JOLANDA MARIE HOWE	Officer	Aug 18 '26	Proposed Sale	100.00	40,000	4,000,000		Aug 18 05:24 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Aug 11 '26	Sale	99.90	6,001	599,510	36,355	Aug 12 05:14 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 10 '26	Option Exercise	2.94	20,000	58,720	214,309	Aug 11 05:41 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 10 '26	Sale	98.92	20,000	1,978,402	194,309	Aug 11 05:41 PM
ERIC BJERKHOLT	Officer	Aug 11 '26	Proposed Sale	99.90	6,001	599,510		Aug 11 04:11 PM
CHRISTOPHER PEETZ	Officer	Aug 10 '26	Proposed Sale	98.92	20,000	1,978,346		Aug 10 04:17 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 03 '26	Sale	105.29	1,840	193,734	1,274	Aug 05 04:26 PM
JOLANDA MARIE HOWE	Officer	Aug 03 '26	Proposed Sale	105.29	1,840	193,734		Aug 03 04:07 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jul 06 '26	Option Exercise	2.94	20,000	58,720	214,309	Jul 08 05:12 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jul 06 '26	Sale	122.27	20,000	2,445,382	194,309	Jul 08 05:12 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jul 06 '26	Sale	122.25	5,000	611,273	42,181	Jul 08 05:07 PM
CHRISTOPHER PEETZ	Officer	Jul 06 '26	Proposed Sale	122.27	20,000	2,445,434		Jul 06 04:10 PM
ERIC BJERKHOLT	Officer	Jul 06 '26	Proposed Sale	122.25	5,000	611,270		Jul 06 04:09 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 01 '26	Sale	120.00	2,721	326,520	3,114	Jul 02 06:01 PM
JOLANDA MARIE HOWE	Officer	Jul 01 '26	Proposed Sale	120.00	2,721	326,520		Jul 01 05:24 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jun 17 '26	Sale	101.95	2,594	264,458	5,835	Jun 18 06:39 PM
JOLANDA MARIE HOWE	Officer	Jun 17 '26	Proposed Sale	101.95	2,594	264,458		Jun 17 04:01 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jun 09 '26	Option Exercise	26.49	2,393	63,391	47,181	Jun 09 09:21 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jun 08 '26	Sale	93.82	5,000	469,077	44,788	Jun 09 09:21 PM
Radovich Peter	PRESIDENT AND COO	Jun 05 '26	Option Exercise	19.19	16,988	326,000	57,260	Jun 08 04:27 PM
ERIC BJERKHOLT	Officer	Jun 08 '26	Proposed Sale	93.81	5,000	469,073		Jun 08 04:20 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jun 01 '26	Option Exercise	2.94	30,000	88,080	224,309	Jun 02 07:50 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jun 01 '26	Sale	95.84	30,000	2,875,103	194,309	Jun 02 07:50 PM
Ramasastry Saira	Director	Jun 01 '26	Sale	100.00	3,977	397,700	0	Jun 02 07:50 PM
CHRISTOPHER PEETZ	Officer	Jun 01 '26	Proposed Sale	95.84	30,000	2,875,107		Jun 01 05:33 PM
SAIRA RAMASASTRY	Director	Jun 01 '26	Proposed Sale	100.00	3,977	397,700		Jun 01 04:04 PM
Ramasastry Saira	Director	May 15 '26	Option Exercise	23.51	2,000	47,020	2,000	May 18 08:32 PM
Ramasastry Saira	Director	May 15 '26	Sale	109.47	2,000	218,940	0	May 18 08:32 PM
SAIRA RAMASASTRY	Director	May 15 '26	Proposed Sale	109.47	2,000	218,940		May 15 04:07 PM
Ramasastry Saira	Director	Apr 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Apr 16 08:40 PM
Ramasastry Saira	Director	Apr 15 '26	Sale	96.90	2,000	193,800	0	Apr 16 08:40 PM
SAIRA RAMASASTRY	Director	Apr 15 '26	Proposed Sale	96.90	2,000	193,800		Apr 15 04:11 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 16 '26	Sale	91.98	7,287	670,243	49,788	Mar 17 07:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Mar 16 '26	Sale	91.98	7,287	670,243	18,864	Mar 17 07:30 PM
Ramasastry Saira	Director	Mar 16 '26	Option Exercise	23.51	2,000	47,020	2,000	Mar 17 07:30 PM
Ramasastry Saira	Director	Mar 16 '26	Sale	90.76	2,000	181,520	0	Mar 17 07:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 16 '26	Sale	91.98	16,515	1,519,015	40,272	Mar 17 07:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 16 '26	Sale	91.98	4,732	435,239	8,429	Mar 17 07:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 16 '26	Sale	91.98	40,985	3,769,714	194,309	Mar 17 07:30 PM
ERIC BJERKHOLT	Officer	Mar 16 '26	Proposed Sale	92.64	7,287	675,068		Mar 17 07:03 PM
Joanne Quan	Officer	Mar 16 '26	Proposed Sale	92.64	7,287	675,068		Mar 17 07:00 PM
Peter Radovich	Officer	Mar 16 '26	Proposed Sale	92.64	16,515	1,529,950		Mar 17 06:58 PM
Jolanda Howe	Officer	Mar 16 '26	Proposed Sale	92.64	4,732	438,372		Mar 17 06:55 PM
Christopher Peetz	Officer	Mar 16 '26	Proposed Sale	92.64	40,985	3,796,850		Mar 17 06:50 PM
SAIRA RAMASASTRY	Director	Mar 16 '26	Proposed Sale	90.76	2,000	181,520		Mar 16 04:04 PM
Radovich Peter	PRESIDENT AND COO	Mar 06 '26	Option Exercise	15.87	5,912	93,823	26,567	Mar 11 04:05 PM
Ramasastry Saira	Director	Feb 13 '26	Option Exercise	23.51	2,000	47,020	2,000	Feb 17 04:38 PM
Ramasastry Saira	Director	Feb 13 '26	Sale	102.09	2,000	204,180	0	Feb 17 04:38 PM
SAIRA RAMASASTRY	Director	Feb 13 '26	Proposed Sale	102.09	2,000	204,180		Feb 13 04:04 PM
Radovich Peter	PRESIDENT AND COO	Feb 02 '26	Sale	103.30	2,631	271,792	20,655	Feb 03 09:45 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '26	Sale	103.30	9,108	940,888	160,294	Feb 03 09:45 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '26	Sale	103.30	968	99,998	4,503	Feb 03 09:45 PM
Jolanda Howe	Officer	Feb 02 '26	Proposed Sale	103.80	968	100,478		Feb 02 08:29 PM
Peter Radovich	Officer	Feb 02 '26	Proposed Sale	103.80	2,631	273,098		Feb 02 08:25 PM
Christopher Peetz	Officer	Feb 02 '26	Proposed Sale	103.80	9,108	945,410		Feb 02 08:21 PM
Jolanda Howe	Officer	Jan 26 '26	Proposed Sale	96.92	842	81,607		Jan 28 06:47 PM
ERIC BJERKHOLT	Officer	Jan 26 '26	Proposed Sale	96.92	1,053	102,057		Jan 28 06:44 PM
Peter Radovich	Officer	Jan 26 '26	Proposed Sale	96.92	3,143	304,620		Jan 28 06:43 PM
Christopher Peetz	Officer	Jan 26 '26	Proposed Sale	96.92	6,831	662,061		Jan 28 06:40 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	96.19	1,053	101,290	43,741	Jan 27 04:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 26 '26	Sale	96.19	3,143	302,331	23,286	Jan 27 04:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 26 '26	Sale	96.19	842	80,994	3,700	Jan 27 04:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 26 '26	Sale	96.19	6,831	657,088	169,402	Jan 27 04:30 PM
Heron Patrick J	Director	Jan 23 '26	Buy	68.48	131,425	8,999,984	459,010	Jan 27 04:14 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 22 '26	Sale	93.33	926	86,419	3,042	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 22 '26	Sale	93.33	1,822	170,039	12,817	Jan 23 05:30 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 22 '26	Sale	93.33	1,421	132,615	42,127	Jan 23 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 22 '26	Sale	93.33	2,382	222,301	20,679	Jan 23 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 22 '26	Sale	93.33	7,098	662,422	163,733	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 20 '26	Sale	90.27	6,911	623,853	11,305	Jan 21 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Jan 16 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Sale	90.99	2,000	181,980	0	Jan 16 04:05 PM
SAIRA RAMASASTRY	Director	Jan 15 '26	Proposed Sale	90.99	2,000	181,980		Jan 15 04:02 PM
Ramasastry Saira	Director	Dec 22 '25	Option Exercise	23.51	5,000	117,550	5,000	Dec 23 06:52 PM
Ramasastry Saira	Director	Dec 22 '25	Sale	80.00	5,000	400,000	0	Dec 23 06:52 PM
GREY MICHAEL G	Director	Dec 19 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 23 06:50 PM
GREY MICHAEL G	Director	Dec 19 '25	Sale	78.00	50,000	3,900,000	0	Dec 23 06:50 PM
SAIRA RAMASASTRY	Director	Dec 22 '25	Proposed Sale	80.00	5,000	400,000		Dec 22 04:03 PM
Ramasastry Saira	Director	Dec 18 '25	Option Exercise	23.51	2,000	47,020	2,000	Dec 19 04:15 PM
Ramasastry Saira	Director	Dec 18 '25	Sale	69.73	2,000	139,460	0	Dec 19 04:15 PM
MICHAEL GREY	Director	Dec 19 '25	Proposed Sale	78.00	50,000	3,900,000		Dec 19 04:05 PM
SAIRA RAMASASTRY	Director	Dec 18 '25	Proposed Sale	69.73	2,000	139,460		Dec 18 04:09 PM
GREY MICHAEL G	Director	Dec 01 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 02 04:04 PM
GREY MICHAEL G	Director	Dec 01 '25	Sale	74.00	50,000	3,700,000	0	Dec 02 04:04 PM
MICHAEL GREY	Director	Dec 01 '25	Proposed Sale	74.00	50,000	3,700,000		Dec 01 04:07 PM
GREY MICHAEL G	Director	Nov 21 '25	Option Exercise	2.94	50,000	146,800	50,000	Nov 25 04:10 PM
GREY MICHAEL G	Director	Nov 21 '25	Sale	70.00	50,000	3,500,000	0	Nov 25 04:10 PM
MICHAEL GREY	Director	Nov 21 '25	Proposed Sale	70.00	50,000	3,500,000		Nov 21 04:09 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Nov 18 '25	Option Exercise	19.24	19,133	368,119	158,034	Nov 20 04:21 PM

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products pipeline includes Maralixibat, Cholbam, Ctexli, Volixibat, Brelovitug, MRM-3379, and Zilurgisertib. The company was founded by Niall O'Donnel, Michael G. Grey, and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

CEO & DirectorMr. Christopher Peetz

Ph.D.Mr. Peter Radovich M.B.A.

M.S.Mr. Eric H. Bjerkholt M.B.A.

Chief Technical OfficerDr. Jean-Luc Girardet Ph.D.

Senior Vice PresidentMr. Andrew McKibben

TARS

Tarsus Pharmaceuticals Inc

PASG

Passage Bio Inc

PHAT

Phathom Pharmaceuticals Inc

MIRM

Mirum Pharmaceuticals Inc

Upgrade your Finviz experience